Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the coronavirus disease 2019 (COVID-19) pandemic, is the worst challenge for a century for international health and financial systems. It was declared a global pandemic on 11 March 2020, 6 weeks after it had first been reported from China as a new respiratory virus.1 By then, 118 000 cases had been reported from 114 countries and 4291 people reported to have lost their lives.1 Only 7 weeks later, as of 5 May, 3 544 222 cases of COVID-19, including 250 977 deaths, have been reported from 187 countries and regions, and maritime quarantine.2
While severity and mortality have been highest in people with underlying morbidities,3 no age group is immune from COVID-19 nor are the rich and famous. Reasons are unclear for more severe disease in males and, at least in the UK and USA, in ethnic minority groups. Members of many governments have been affected, including the British Prime Minister Boris Johnson, now discharged from hospital after a spell in intensive care. Reported mortality varies widely between countries with apparently similar economic development.4 Influences on reported case fatality ratios—the number of deaths divided by the number of reported cases—include the number tested, who is tested, test accuracy, demographics for age and comorbidity, and capacity and standards of healthcare staff and facilities. More reliable data, reported mortality, on 5 May ranged in the worst affected countries in Europe, for example, from 80 in Germany to 423 in the UK, 481 in Italy and 684 in Belgium per million in the general population2 and in North America 102 per million in Canada but 204 per million in the USA.2 These figures may reflect considerable underestimates of actual mortality, as deaths from COVID-19 among care home …
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests DS is the President of the Fellowship of Postgraduate Medicine, for which Health Policy and Technology is an official journal. During 2014, he was a physician and pharmacologist in Rwanda within the US AID and US CDC Human Resources for Health programme.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
Author note This editorial is to be published simultaneously with a similar editorial in Health Policy and Technology.